Core Viewpoint - Belite Bio is experiencing positive market sentiment due to the successful results of its experimental drug for a rare genetic eye disease, leading to a new price target set by H.C. Wainwright, indicating potential growth in the company's market performance [1][2][5] Company Performance - Belite Bio's stock is currently priced at $147.01, reflecting a 6.96% increase following the positive trial results [3][5] - The stock has shown significant volatility, with a trading range between $130.06 and $159.71, and a yearly high of $154.99 and a low of $49 [3] - The company's market capitalization is approximately $5.13 billion, indicating a substantial presence in the biopharmaceutical industry [4] Market Sentiment - H.C. Wainwright has set a new price target of $185 for Belite Bio, representing a 20.4% potential upside from its current trading price [1][5] - The positive trial results and the new price target have likely driven active investor interest, as evidenced by a trading volume of 651,051 shares [4]